Vernalis receives milestone payment in Hsp90 inhibitor collaboration

20-Jul-2009 - USA

Vernalis plc announced the achievement of a milestone under the company’s collaboration with Novartis on the oncology target Hsp90. The $1.5 million milestone was triggered by the start of Phase I clinical trials of an oral Hsp90 inhibitor in a range of solid tumours.

Ian Garland, CEO of Vernalis said “We are delighted that Novartis is now progressing two Hsp90 inhibitors in human clinical studies. Milestones and royalties are receivable on both programmes as they progress through development and into commercialisation."

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

How to use antibodies to control chemical reactions - Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies

How to use antibodies to control chemical reactions - Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies

Novel gene variants identified in male breast cancer

Ariadne Genomics and Jubilant Biosys Announce Strategic Alliance - Providing Curated Metabolic, Signaling, and Disease Pathway Databases as an Add-on to Pathway Analysis Software

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

TranScrip Partners appoints David Oxlade as Chairman of the Board

Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents

Intercell announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections - Second part of the study in the target population of elderly subjects will be initiated

Excellent early results in large OvPlex ovarian cancer biomarker study

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board